Current Status and Future Directions for Immunotherapy in Hepatocellular Carcinoma

Learn how to leverage immune checkpoint inhibitors for optimal management of HCC across different settings with expert-authored slides and an on-demand Webcast capturing a dynamic live CCO Webinar.

Share

Program Content

Activities

Immunotherapy in HCC
Immunotherapy in Hepatocellular Carcinoma
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: October 14, 2020

Expires: October 13, 2021

First-Line IO in HCC
IO Combinations in First-line Advanced HCC: Current Evidence and Ongoing Trials
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: October 14, 2020

Expires: October 13, 2021

IO in Early HCC
IO Combinations in Early or Intermediate-Stage HCC: Current Evidence and Ongoing Trials
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: October 14, 2020

Expires: October 13, 2021

<i>EP</i>: IO in HCC
ExpressPoints: Current Status and Future Directions for Immunotherapy in Hepatocellular Carcinoma
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: October 26, 2020

Expires: October 25, 2021

Activities

Immunotherapy in HCC
Current Status and Future Directions for Immunotherapy in Hepatocellular Carcinoma
Congratulations: You achieved a completion on 04/09/2022

Faculty

cover img faculity

Ghassan K. Abou-Alfa, MD

Assistant Attending Physician
Memorial Sloan Kettering Cancer Center
Assistant Professor
Weill Medical College at Cornell University
New York, New York

cover img faculity

Ghassan K. Abou-Alfa, MD, MBA

Attending Physician
Memorial Sloan Kettering Cancer Center
New York, New York

cover img faculity

Peter R. Galle, MD, PhD

Chairman
First Department of Internal Medicine
University Medical Center
Mainz, Germany

cover img faculity

Bruno Sangro, MD, PhD

Professor of Medicine
Head

Liver Unit and HPB Oncology Area
Universidad de Navarra
Pamplona, Spain

Provided by

ProCE Banner

Supporters

Supported by an educational grant from

AstraZeneca